GLP-3 (Retatrutide) Pen 20 mg Dual-Chamber

20mg299,00 € incl. VAT

GLP-3 (Retatrutide) Pen 20 mg Dual-Chamber: dual-chamber pen with 20 mg of lyophilised retatrutide (triple GIP/GLP-1/glucagon receptor agonist) and 1 mL of water in separate chambers of one cartridge. Activation mixes them to 20 mg/mL, so the peptide ships and stores as a dry powder. Certificate of Analysis coming soon. For laboratory research use only.

Pre-order

Shipping from 11,93 € · Free EU shipping over 200 €

SKU: GLP3-20MG-PEN-DUAL Category:

Product specifications

Quantity20mg
Unit1 pre-filled pen
FormatDual-chamber pen (powder and solvent, mixed on activation)
Concentration20 mg/mL after mixing with 1 mL water
Storage2–8 °C, protected from light
Certificate of AnalysisComing soon

Description

Research use only. Sold for laboratory research. Not a medicine, and not for human or veterinary use.

Pre-order

This pen is being prepared for its first production run. Orders placed now are reserved and ship as soon as stock arrives; you will get an email with tracking the day it leaves.

What is retatrutide?

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide that activates three receptors at once: GIP, GLP-1 and glucagon. This is why it is called a triple agonist, or "GLP-3". GLP-1 and GIP activity act on appetite, satiety and insulin secretion; the glucagon component adds an effect on energy expenditure and fat breakdown in the liver. It is an investigational compound in phase 3 trials and is not approved as a medicine anywhere.

What the research shows

  • Body weight. In the phase 2 obesity trial (Jastreboff et al., NEJM 2023; 338 adults, 48 weeks), mean weight change was −24.2% at 12 mg weekly, against −2.1% with placebo. At 24 weeks the 12 mg group was already at −17.5%.
  • Phase 3. Topline results from the first phase 3 trial (TRIUMPH-4, announced in December 2025) reported mean weight loss of 28.7% at 68 weeks on 12 mg, against 2.1% with placebo, in adults with obesity and knee osteoarthritis. Full results have not yet been published in a journal.
  • Blood glucose. In adults with type 2 diabetes (Rosenstock et al., Lancet 2023), HbA1c fell by up to about 2.0 percentage points at 24 weeks.
  • Liver fat. In a substudy of participants with fatty liver (Sanyal et al., Nature Medicine 2024), liver fat fell by more than 80% at the two highest doses after 24 weeks.
  • Lipids and blood pressure. Triglycerides, LDL cholesterol and blood pressure improved alongside the weight change.

Side effects reported in studies

Mostly gastrointestinal and dose-related: nausea, diarrhoea, vomiting and constipation, more frequent during dose escalation and with a higher starting dose. A dose-dependent rise in heart rate was observed, peaking around week 24 and then declining.

Doses reported in published studies

The phase 2 trial tested 1, 4, 8 and 12 mg once weekly by subcutaneous injection. The higher-dose groups started at 2 mg or 4 mg and stepped up every 4 weeks; starting at 2 mg produced fewer gastrointestinal effects than starting at 4 mg. The phase 3 trials use weekly maintenance doses of up to 12 mg.

This section summarises the doses used in the published literature. It is not a recommendation.

About the dual-chamber format

Peptides are most stable as a dry, lyophilised powder and start to degrade slowly once they are in solution. A dual-chamber cartridge keeps the two apart: the lyophilised peptide sits in the front chamber, the solvent in the rear chamber, and a stopper seals one from the other. Nothing mixes during storage or shipping.

On first use the pen is activated. Pushing the rear plunger moves the middle stopper into a bypass groove in the glass, the solvent flows around it into the powder chamber, and the peptide dissolves inside the cartridge. From that point the pen works like a pre-mixed pen. The result is the shelf stability of a sealed vial with the convenience of a pen, and no reconstitution step by hand.

Supplied as one pre-filled pen, without other accessories.

Pen or vial?

PenVial
Form on arrivalSolution in a cartridge (dual-chamber: powder and solvent, mixed on activation)Lyophilised powder
ReconstitutionNot neededDone by the user with bacteriostatic water
MeasuringDial, fixed volume per clickSyringe, calculated per draw
Handling stepsOneSeveral
Price per mgHigherLower
Best forConvenience and repeatable volumesLowest cost and the longest unopened shelf life

Prefer the lyophilised vial? See GLP-3 (Retatrutide) 10mg.

Storage

Keep the pen refrigerated at 2–8 °C, in its box and away from light. Do not freeze. Do not use if the solution is cloudy, discoloured or contains particles. Short temperature excursions during shipping are expected and are covered by insulated packaging.

Quality and Certificate of Analysis

Certificate of Analysis: coming soon. The report for this lot is in progress and will be published on this page as soon as the laboratory releases it.

Frequently asked questions

When will my pre-ordered GLP-3 (Retatrutide) Pen 20 mg Dual-Chamber ship?

As soon as the first production run arrives. You receive tracking by email on the day it leaves.

Does the GLP-3 (Retatrutide) Pen 20 mg Dual-Chamber need to stay cold?

Yes. Keep it at 2–8 °C. It ships in insulated packaging.

Is there a Certificate of Analysis for the GLP-3 (Retatrutide) Pen 20 mg Dual-Chamber?

It is coming soon. The report for this lot is in progress and will be published on the product page.

What is in the box?

One pre-filled pen. Needles and other accessories are not included at the moment.

Is it the same substance as the vial?

Yes. It is the same substance in a different format.

Batch test records

Certificate of Analysis coming soon. The report for this lot will be published here as soon as the laboratory releases it.